ストックスクリーナーアプリを入手
28.38
5.39%
-1.615
前日終値:
$29.99
開ける：
$29.69
24時間の取引高:
188.15K
Relative Volume:
0.36
時価総額：
$1.06B
収益：
$272.30M
当期純損益:
$-5.14M
株価収益率:
-173.55
EPS:
-0.1635
ネットキャッシュフロー:
$42.76M
1週間 パフォーマンス:
-0.23%
1か月 パフォーマンス:
-7.87%
6か月 パフォーマンス:
-29.99%
1年 パフォーマンス:
-24.45%
1日の値動き範囲:
$28.08
$30.05
1週間の範囲:
$28.30
$30.28
52週間の値動き範囲:
$26.96
$54.85
Harrow Inc Stock (HROW) Company Profile
Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
28.38 | 1.06B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
20.91 | 66.81B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.71 | 48.65B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.645 | 38.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.62 | 32.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
602.04 | 25.82B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-09 | 開始されました | Leerink Partners | Outperform |
| 2025-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 開始されました | BTIG Research | Buy |
| 2025-06-10 | 開始されました | William Blair | Outperform |
| 2025-02-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-04 | 繰り返されました | B. Riley Securities | Buy |
| 2024-04-11 | 開始されました | Craig Hallum | Buy |
| 2022-09-08 | 再開されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2021-09-24 | 開始されました | Aegis Capital | Buy |
| 2021-07-02 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Harrow Inc (HROW) 最新ニュース
Harrow, Inc. (HROW) stock price, news, quote and history - Yahoo Finance UK
Harrow Inc. (HROW) Climbs 5.54% as Shares Reclaim Ground Toward $30 ResistanceRetail Volume - https://www.dars.gov.et/
Harrow Inc. (HROW) Climbs 5.54% as Shares Reclaim Ground Toward $30 ResistanceUp Down Ratio - siam.in
Harrow stock seeks rebound - Nashville Post
Do Options Traders Know Something About Harrow Stock We Don't? - Zacks Investment Research
Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
TYRVAYA is the only FDA-approved nasal spray for dry eye. Harrow acquired its rights outside Japan. - Stock Titan
Ocular Therapeutix, Inc.Common Stock (NQ: OCUL - The Chronicle-Journal
Is Harrow Inc (HROW) a Bargain After 5.7% Drop? GF Value Says Un - GuruFocus
Harrow at Cantor healthcare conference: long view, bigger eye-care bet - investing.com
HROW Initiates Coverage On Harrow -- Outperform Rating by Leerin - GuruFocus
Harrow (NasdaqGM:HROW) Stock Forecast & Analyst Predictions - Simply Wall Street
Andrew R. Boll Assumes Principal Accounting Officer Role at Harrow (NASDAQ: HROW) - Kalkine Media
Harrow Inc. (HROW) Slides 2.96% to $37.4, Approaches Support at $35.53Risk Reward Setups - dars.gov.et
Harrow Inc. (HROW) Slides 2.96% to $37.4, Approaches Support at $35.53Tick Index - dars.gov.et
Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView
Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com
Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenEarnings Risk Report - dars.gov.et
Harrow Inc stock gains as analysts see strong revenue growth ahead - ad-hoc-news.de
Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus
Harrow to Participate in Three Investor Conferences in September - GlobeNewswire
Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move: Shares Move Lower 2.81% at the CloseEarnings Recovery Stocks - dars.gov.et
HROW | Harrow, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan
Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn
What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st
Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st
Nutrien (NTR) Results Review: EPS Misses Its Estimate in the Available Record; Trading Response: Shares Move 1.59% Up in the Current UpdatePositive Surprise Momentum - dars.gov.et
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com Canada
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com India
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st
Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneSweep Order Flow - dars.gov.et
HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn
Harrow Inc (HROW) 財務データ
収益
当期純利益
現金流量
EPS
Harrow Inc (HROW) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER |
Aug 14 '26 |
Option Exercise |
35.96 |
11,250 |
404,550 |
11,250 |
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER |
Aug 14 '26 |
Sale |
40.00 |
11,250 |
450,000 |
0 |
| Graves Adrienne L | Director |
May 18 '26 |
Buy |
31.07 |
1,000 |
31,070 |
1,000 |
| SILVERNAIL LAUREN P | Director |
May 18 '26 |
Buy |
31.00 |
1,000 |
31,000 |
1,000 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Buy |
30.20 |
10,000 |
302,000 |
2,996,130 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
May 14 '26 |
Buy |
29.90 |
3,500 |
104,650 |
814,679 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Sale |
39.67 |
138,263 |
5,485,184 |
59,428 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Sale |
39.15 |
60,309 |
2,361,242 |
63,691 |
| Opaleye Management Inc. | 10% Owner |
Feb 27 '26 |
Sale |
54.18 |
5,000 |
270,900 |
65,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
2.14%
2.23%
大文字化:
|
ボリューム (24 時間):